Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 7:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 2,347 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Intravenous Clear all
Completed Phase 1 Interventional

Safety Study of TPI-287 to Treat CBS and PSP

NCT02133846
View directory record Official record
Conditions
Primary Four Repeat Tauopathies (4RT), Corticobasal Syndrome (CBS), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)
Interventions
TPI 287 2 mg/m2, TPI-287 20 mg/m2, Placebo, TPI-287 6.3 mg/m2
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years to 85 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Birmingham, Alabama • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Oct 14, 2026, 7:23 PM EDT
Not listed Phase 2 Interventional

Evaluate Efficacy, PK, and Safety of FB825 in Adults With Atopic Dermatitis

NCT04413942
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
FB825, Placebo
Biological · Other
Lead sponsor
Oneness Biotech Co., Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
18
States / cities
Beverly Hills, California • Encino, California • Huntington Beach, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 14, 2026, 7:23 PM EDT
Terminated Phase 3 Interventional

Outpatient Treatment With Anti-Coronavirus Immunoglobulin

NCT04910269
View directory record Official record
Conditions
COVID, SARS-CoV2 Infection, Covid19
Interventions
Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG), Placebo
Biological · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
16
States / cities
Tucson, Arizona • Mather, California • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 14, 2026, 7:23 PM EDT
Completed Phase 4 Interventional Results available

Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery

NCT02556918
View directory record Official record
Conditions
Hyperglycemia
Interventions
Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Oct 14, 2026, 7:23 PM EDT
Terminated Not applicable Interventional Results available

Anti-inflammatory Treatment at the Onset of Necrotizing Enterocolitis (NEC) in Preterm Infants

NCT01156480
View directory record Official record
Conditions
Necrotizing Enterocolitis
Interventions
hydrocortisone, placebo
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
0 Days to 6 Months
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 14, 2026, 7:23 PM EDT
Completed Phase 2 Interventional Results available

A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C

NCT03420768
View directory record Official record
Conditions
Hepatic Cirrhosis, Liver Fibrosis
Interventions
BMS-986263, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2022 · Synced Oct 14, 2026, 7:23 PM EDT
Completed Phase 1 Interventional

End-stage Renal Disease (ESRD) Pilot Study

NCT03787368
View directory record Official record
Conditions
Renal Dialysis
Interventions
BAY1213790, 0.9% sodium chloride solution
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 80 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Chula Vista, California • Bradenton, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 14, 2026, 7:23 PM EDT
Recruiting Phase 2 Interventional

A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

NCT07221474
View directory record Official record
Conditions
Squamous Non-small Cell Lung Cancer
Interventions
Intismeran Autogene, Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel, Placebo
Biological · Drug · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
11
States / cities
Tampa, Florida • Ann Arbor, Michigan • St Louis, Missouri + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 14, 2026, 7:23 PM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy

NCT07287982
View directory record Official record
Conditions
Spinal Muscular Atrophy (SMA)
Interventions
ARGX-119 IV, Placebo IV
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
5 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
16
States / cities
Little Rock, Arkansas • San Diego, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 14, 2026, 7:23 PM EDT
Completed Phase 3 Interventional Results available

Analgesic Efficacy of Repeated Doses of Intravenous (IV) Acetaminophen in Post-operative Pediatric Spine Fusion Patients

NCT01394718
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Intravenous Acetaminophen, Placebo
Drug · Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
10 Years to 18 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Oct 14, 2026, 7:23 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

NCT00401843
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Siltuximab, Bortezomib, Placebo, Dexamethasone
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
11
States / cities
Greenbrae, California • Los Angeles, California • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 14, 2026, 7:23 PM EDT
Withdrawn Phase 4 Interventional

Double Blind Randomized Placebo Controlled Trial of Natrecor in Acute Decompensated Heart Failure With Normal EF

NCT00505791
View directory record Official record
Conditions
Heart Failure, Congestive, Dyspnea, Pulmonary Edema
Interventions
Nesiritide
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 11, 2015 · Synced Oct 14, 2026, 7:23 PM EDT
Terminated Phase 2 Interventional

Placebo Controlled, Randomized, Double-blind, Multi-center Study to Investigate the Efficacy and Tolerability of BAY58-2667

NCT00559650
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Placebo, Cinaciguat (BAY58-2667)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
San Diego, California • Washington D.C., District of Columbia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 14, 2026, 7:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Intravenous Alcohol Administration Using BrAc Method in Healthy Subjects With and Without a Family History of Alcoholism

NCT00612352
View directory record Official record
Conditions
Alcoholism
Interventions
Ethanol High Dose, Ethanol Low Dose, and Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 30 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2015
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 14, 2026, 7:23 PM EDT
Completed Phase 2 Interventional

Repinotan in Patients With Acute Ischemic Stroke

NCT00044915
View directory record Official record
Conditions
Stroke, Acute Ischemic Stroke
Interventions
Repinotan HCl (BAYX3702), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
782 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
28
States / cities
Los Angeles, California • Oceanside, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2009 · Synced Oct 14, 2026, 7:23 PM EDT
Completed Phase 2 Interventional

Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)

NCT04295538
View directory record Official record
Conditions
Spinal Cord Injury (SCI)
Interventions
Elezanumab, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
22
States / cities
Sacramento, California • Atlanta, Georgia • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 14, 2026, 7:23 PM EDT
Completed Phase 2 Interventional Results available

SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI)

NCT04344184
View directory record Official record
Conditions
COVID-19, Lung Injury, Acute, Kidney Injury
Interventions
L-ascorbic acid, Placebo
Drug · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 14, 2026, 7:23 PM EDT
Completed Phase 1 Interventional

A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease

NCT02353598
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Crenezumab dose level 1, Crenezumab dose level 2, Crenezumb dose level 3, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
13
States / cities
Phoenix, Arizona • San Francisco, California • Delray Beach, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 14, 2026, 7:23 PM EDT
Terminated Phase 3 Interventional

A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer

NCT00738387
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
ASA404, Placebo, docetaxel
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
88
States / cities
Huntsville, Alabama • Tucson, Arizona • Bentonville, Arkansas + 76 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2020 · Synced Oct 14, 2026, 7:23 PM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Low-Dose Intravenous Ketamine for Adolescents With Depression and Suicidal Ideation in the Emergency Department

NCT05217706
View directory record Official record
Conditions
Depression, Suicidal Ideation
Interventions
Ketamine, normal Saline
Drug
Lead sponsor
Rady Children's Hospital, San Diego
Other
Eligibility
12 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 14, 2026, 7:23 PM EDT
Completed Phase 4 Interventional Results available

Effect IV Ibuprofen and Inflammatory Responses

NCT01938040
View directory record Official record
Conditions
Gallbladder Disease
Interventions
ibuprofen, sugar water/placebo
Drug · Other
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Newark, New Jersey • Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 21, 2016 · Synced Oct 14, 2026, 7:23 PM EDT
Withdrawn Phase 2 Interventional

Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza Infection

NCT01992276
View directory record Official record
Conditions
Influenza
Interventions
CR8020, CR6261, Placebo
Biological
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
21
States / cities
Fresno, California • Stanford, California • Washington D.C., District of Columbia + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Oct 14, 2026, 7:23 PM EDT
Completed Phase 3 Interventional Results available

A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein

NCT02435433
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Ramucirumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
8
States / cities
Daly City, California • Los Angeles, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Oct 14, 2026, 7:23 PM EDT
Completed Phase 1 Interventional

Multiple Ascending Dose Study of MEDI1341 in Patients With Parkinson's Disease

NCT04449484
View directory record Official record
Conditions
Parkinson's Disease
Interventions
MEDI1341, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Long Beach, California • Hallandale, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2022 · Synced Oct 14, 2026, 7:23 PM EDT